Alexander G. Dragnich

Alexander G. Dragnich

Auto-generated profile, based on publicly available information

Alexander G. Dragnich

Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2026 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
MAMichaela Restivo Anderson
Michaela Restivo Anderson
SASelim M. Arcasoy
Selim M. Arcasoy
CBChristian Benden
Christian Benden
MBMarie Budev
Marie Budev
MCMarlene Cano
Marlene Cano
JSJonathan P. Singer
Jonathan P. Singer

12 August 2026 in JHLT Open
Verified
Journal Article
Open access
ATAlexandra H. Toporek
Alexandra H. Toporek
WGWhitney D. Gannon
Whitney D. Gannon
MCMichael P. Croglio
Michael P. Croglio
DMDaniel Motta-Calderon
Daniel Motta-Calderon
ADAlexander G. Dragnich
Alexander G. Dragnich
ATAnil J. Trindade
Anil J. Trindade
The pragmatic aspects of routine lung transplant recipient management are poorly described. We performed an international survey study to characterize management of stable lung transplant recipients who are beyond the initial post-transplant year. We obtained survey responses from 72 distinct lung transplant programs in 15 countries. Stable patients are monitored a median of every 3-months (IQR 3-3.25) in the ambulatory setting. Visits are accompanied by diagnostic laboratory assessments, spirometry, and chest X-ray imaging. Most centers perform between-clinic surveillance every 1-month (IQR 1-1.5) with diagnostic laboratory testing. We identified the frequency of monitoring of donor-specific antibodies [median 6 months (IQR 3-6)], chest computed tomography [median 12 months (IQR 12-12)], and other ancillary testing. A majority of stable patients are managed on a maintenance immunosuppression regimen of tacrolimus (preferred goal trough 8-10 ng/ml), mycophenolate, and prednisone (preferred dose of 5 mg daily). Dose reduction of immunosuppression occurs for cytopenias, recurrent infection, malignancy, and short telomere syndromes at most centers. Methodologies and frequencies for malignancy screening are described. While routine care of lung transplant recipients is heterogeneous, there are potential areas of consensus in practice patterns.

13 January 2025 in Clinical Transplantation
Verified
Journal Article
Open access
ADAlexander G. Dragnich
Alexander G. Dragnich
KCKaitlyn C. Chapin
Kaitlyn C. Chapin
KXKe Xu
Ke Xu
JLJinyuan Liu
Jinyuan Liu
LLLoren Lipworth
Loren Lipworth
ATAnil J. Trindade
Anil J. Trindade
The importance of mental toughness on lung transplant outcomes is unknown. We performed a pilot study to assess whether pretransplant grit and resilience are associated with short‐term posttransplant outcomes. We enrolled 31 lung transplant candidates, of whom 7 (26%) had greater mental toughness, defined as the upper tertile for both grit and resilience within our cohort. There were no differences in baseline characteristics between patients with higher and lower mental toughness. Greater mental toughness was associated with a shorter hospital length of stay (LOS) [12 days (interquartile range, IQR 10–12) vs. 17 days (IQR 14–24), p = 0.02] and reduced posttraumatic stress severity [median 0 (IQR 0–2) vs. 6.5 (IQR 4–9), p < 0.01]. On multivariable analyses adjusting for age and Duke Activity Status Index, greater mental toughness was associated with a shorter hospital LOS [beta = −11.96 (95% CI 0.05–23.86), p < 0.05] and reduced PTSD [beta = −10.7 (95% CI −21.6–0.04), p = 0.053]. Lung transplant candidates with greater mental toughness may have improved short‐term outcomes.